Literature DB >> 15377706

Massive reduction of tumour load and normalisation of hyperprolactinaemia after high dose cabergoline in metastasised prolactinoma causing thoracic syringomyelia.

S H M van Uum1, N van Alfen, P Wesseling, E van Lindert, G F F M Pieters, P Nooijen, A R M M Hermus.   

Abstract

In 1970 a 20 year old woman presented with a pituitary chromophobe adenoma for which she underwent transfrontal pituitary surgery. In 1978 she had to be reoperated on because of local tumour recurrence, resulting in hypopituitarism. Bromocriptine (5 mg/day) was given for 15 years, but the plasma prolactin levels remained elevated. In 2000 the patient presented with signs and symptoms suggestive of a spinal cord lesion at the mid-thoracic level. A magnetic resonance imaging (MRI) scan showed an extensive leptomeningeal mass extending from the brainstem to L5, with a thoracic syringomyelia at the T7-T8 level. The plasma prolactin level was very high (5114 microg/l). A biopsy showed the presence of a metastasised prolactinoma. On administration of high dose cabergoline, 0.5 mg twice a day orally, the plasma prolactin levels decreased within one month and then normalised within 26 months. Tumour load reduced considerably but unfortunately, her signs and symptoms did not improve. This case illustrates that a high dose dopamine agonist might be an important therapeutic option in patients with a metastasised prolactinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15377706      PMCID: PMC1738774          DOI: 10.1136/jnnp.2003.028118

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  1 in total

1.  A scoping review to understand the indications, effectiveness, and limitations of cabergoline in radiological and biochemical remission of prolactinomas.

Authors:  Rakesh Mishra; Subhas K Konar; Adesh Shrivastava; Pradeep Chouksey; Sumit Raj; Amit Agrawal
Journal:  Indian J Endocrinol Metab       Date:  2022-02-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.